CA2244836A1 - Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite - Google Patents

Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite

Info

Publication number
CA2244836A1
CA2244836A1 CA 2244836 CA2244836A CA2244836A1 CA 2244836 A1 CA2244836 A1 CA 2244836A1 CA 2244836 CA2244836 CA 2244836 CA 2244836 A CA2244836 A CA 2244836A CA 2244836 A1 CA2244836 A1 CA 2244836A1
Authority
CA
Canada
Prior art keywords
antidiabetic
compounds
antiobesity agents
benzoheterocyclic derivatives
antiobesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2244836
Other languages
English (en)
Other versions
CA2244836C (fr
Inventor
Alan D. Adams
Joel P. Berger
Gregory D. Berger
Kenneth J. Fitch
Donald W. Graham
Anthony B. Jones
Derek Von Langen
Mark D. Leibowitz
David E. Moller
Arthur A. Patchett
Conrad Santini
Soumya P. Sahoo
Richard L. Tolman
Richard B. Toupence
Thomas F. Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck & Co., Inc.
Alan D. Adams
Joel P. Berger
Gregory D. Berger
Kenneth J. Fitch
Donald W. Graham
Anthony B. Jones
Derek Von Langen
Mark D. Leibowitz
David E. Moller
Arthur A. Patchett
Conrad Santini
Soumya P. Sahoo
Richard L. Tolman
Richard B. Toupence
Thomas F. Walsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604234.6A external-priority patent/GB9604234D0/en
Application filed by Merck & Co., Inc., Alan D. Adams, Joel P. Berger, Gregory D. Berger, Kenneth J. Fitch, Donald W. Graham, Anthony B. Jones, Derek Von Langen, Mark D. Leibowitz, David E. Moller, Arthur A. Patchett, Conrad Santini, Soumya P. Sahoo, Richard L. Tolman, Richard B. Toupence, Thomas F. Walsh filed Critical Merck & Co., Inc.
Priority claimed from PCT/US1997/001749 external-priority patent/WO1997028137A1/fr
Publication of CA2244836A1 publication Critical patent/CA2244836A1/fr
Application granted granted Critical
Publication of CA2244836C publication Critical patent/CA2244836C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2244836 1996-02-02 1997-01-31 Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite Expired - Fee Related CA2244836C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1108096P 1996-02-02 1996-02-02
US60/011,080 1996-02-02
GB9604234.6 1996-02-28
GBGB9604234.6A GB9604234D0 (en) 1996-02-28 1996-02-28 Antidiabetic agents
US3443496P 1996-12-23 1996-12-23
US60/034,434 1996-12-23
PCT/US1997/001749 WO1997028137A1 (fr) 1996-02-02 1997-01-31 Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite

Publications (2)

Publication Number Publication Date
CA2244836A1 true CA2244836A1 (fr) 1997-08-07
CA2244836C CA2244836C (fr) 2007-05-01

Family

ID=29424632

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2244836 Expired - Fee Related CA2244836C (fr) 1996-02-02 1997-01-31 Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite

Country Status (1)

Country Link
CA (1) CA2244836C (fr)

Also Published As

Publication number Publication date
CA2244836C (fr) 2007-05-01

Similar Documents

Publication Publication Date Title
AU1856397A (en) Heterocyclic derivatives as antidiabetic and antiobesity agents
AU2115997A (en) Antidiabetic agents
AU2250797A (en) Antidiabetic agents
EP1011651A4 (fr) Methode de traitement du diabete et d'etats pathologiques associes
AU3115395A (en) Dihydrobenzofuranes
ZA200106107B (en) Substituted porphyrins.
ATE198708T1 (de) Verwendung von makrolid-verbindungen gegen augenerkrankungen
EP1071474A4 (fr) Porphyrines substituees
DE69434313D1 (de) Superoxiddismutase memetika
DE69813898D1 (de) Substituierte porphyrinen
CA2201652A1 (fr) Utilisation de sdg purifie comme antioxydant
ITMI931780A1 (it) Tropil 7-azaindolil-3-carbossiamidi
DE69635304D1 (de) Faenger fuer oxidantien
CA2244836A1 (fr) Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite
AU3166295A (en) Imidazopyridine-azolidinones
EP1067138A4 (fr) Derives d'hydroxyproline
AU7381991A (en) Hydroxymethyl-indolizidines and quinolizidines
CA2563381A1 (fr) Utilisation de sdg purifie comme antioxydant
DE29611403U1 (de) Darmbehandlungsmittel zur mikrobiellen Stabilisierung von Naturdärmen
CA2195663A1 (fr) Dihydrobenzofurane
IT1264978B1 (it) Piridotiazine e piridotiazepine ad attivita' antiasmatica
NO995860L (no) Desinfiserende blanding og fremgangsmåte ved desinfisering av overflater

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed